Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (579)	9/3/2003 11:29:39 AM
From: tuck	Read Replies (1) \| Respond to of 897

From Briefing.com: >>7:28AM Antigenics: FDA places partial clinical hold on Phase III trial (AGEN) 14.05: Co announces that the FDA has requested additional product characterization information from Antigenics. Pending receipt and acceptance of such information, the agency is placing on partial clinical hold the Phase III trials of Oncophage under its investigational new drug application, which includes trials in kidney cancer and metastatic melanoma. The FDA said that safety was not an issue and that patients already enrolled in the Phase III studies could proceed with vaccination. << Maybe the BSCP will finally catch a break. On another subject, does anyone feel GPRO is getting ahead of itself? PEG ratio is over 2, and insiders, who had been buying in the spring in the low 20s, are now starting to lighten a bit in low 60s. In the watchlist it goes. Cheers, Tuck